A hybridoma clone secreting a monoclonal antibody, designated MA158.2, that reacts with an antigen ex pressed on lymphokine-treated macrophages was produced by fusion of mouse myeloma cells with rat spleen cells immunized against C57BL/6 peritoneal macrophages rendered tumoricidal in vitro by incubation with the lymphokine macrophageactivating factor. The specificity of the antibody for activated macrophages and lack of reactivity with histologically diverse cell types was determined by radioimmune indirect binding and flow cytometry. MA158.2 antibody binds to mouse peritoneal macrophages elicited by nonspecific inflammatory agents and to tumoricidal macrophages elicited with Corynebacterium parvum. Resident peritoneal, splenic, and alveolar macrophages were only weakly positive. Several macrophage cell lines (P388D1, WEH1-231, J774, RAW 264.7), murine fibroblasts, and neutrophils did not bind detectable amounts of MA158.2. Radioimmune indirect binding analysis demonstrated that cell suspensions prepared from C57BL/6 mouse spleen, thymus, and lymph node as well as polymorphonuclear leukocytes, lymphocytes, and T-and B-cell murine lymphomas were MA158.2 negative. Expression of the reactive antigen on the macrophage cell surface was enhanced 3-fold following in vitro activation of elicited macrophages with macrophage-activating factor and the kinetics of activation to the tumoricidal state paralleled the increased expression of the antigen recognized by MA158.2. MA158.2 is a rat IgG2a antibody containing a single specific heavy and light chain that does not detect a polymorphic determinant. This monoclonal antibody will be a useful tool for monitoring the efficacy of agents in activating murine macrophages to the tumoricidal state and in analyzing the sequence of biochemical events that culminate in macrophage activation.
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Macrophages (MO) are an important effector cell in the recognition and destruction of neoplastic cells (1, 2) , and amplification of MO-mediated tumoricidal activity could provide a useful modality for adjuvant therapy of neoplasia. The term "activated" MO is an operational definition and its use is often extended to MO displaying enhanced phagocytic (3), or microbicidal properties (or both) (4, 5) in response to a vanety of inflammatory stimuli, but which lack tumoricidal activity. In 'this article the term activated will be restricted to those MO that display tumoricidal activity against the B16 melanoma.
MO activation is believed to involve a complex sequence of phenotypic changes that are acquired in stepwise fashion, resulting in the development of microbicidal activity followed by what appears to be the ultimate step in activation, expression of tumoricidal capacity (6) (7) (8) (9) (10) (11) carbon particles and showed positive staining for nonspecific esterase (17) .
Murine peripheral blood monocytes were obtained by cardiac puncture and harvested in acid-citrate/dextrose, and erythrocytes were lysed by hypotonic treatment (18) . Lymphoid organs such as spleen, thymus, and peripheral lymph node were obtained from 3-to 4-wk-old mice. For analysis of cells maintained in suspension, cells were resuspended in Falcon no. 2053 tubes at a density of 5 x 105 per ml in Dulbecco's modified Eagle medium (DME medium) or DME medium containing MO-activating factor (MAF) and incubated for 24 hr before antibody binding analysis. Cell viability, as determined by trypan blue dye exclusion, was always >85%.
Lymphokine. A lymphokine preparation containing MAF activity was obtained from cell-free supernatants from cultures of normal F344 rat lymphocytes incubated for 48 hr with immobilized concanavalin A (Pharmacia), as described elsewhere (19) . Control preparations were obtained from normal rat lymphocyte cell-free supernatants harvested under the same 'conditions from' lymphocyte cultures not exposed to concanavalin A.
Cell Lines. The following cell lines were obtained from American Type Culture Collection: J774.1 (20) ; P388D1 (20) ; WEH1-231 (20) ; RAW-264 (20) ; SP2/0-Agl4 (21); YAC-1 (22); X63-Ag8 (23) . All lines were maintained in DME medium containing 10% fetal bovine serum (CDME medium).
Antisera. (AcM4) were washed three times with DME medium and harvested with a rubber policeman. Cell viability, as determined by trypan blue dye exclusion, was between 40% and 60%. Lewis rats were primed by intraperitoneal and subcutaneous injection of 2 x 107 AcMO in complete Freund's adjuvant (GIBCO). Two weeks later they were inoculated in a similar fashion but by using incomplete adjuvant. Spleens were removed 3 days after a final inoculation of AcM4 administered intravenously and fused with the'SP2/0-Agl4 myeloma line (21) following a previously described procedure (31) . Characterization of MA158.2. Ouchterlony analysis was performed by using subclass-specific antisera (Miles). To obtain biosynthetically labeled antibody for chain analysis, hybridoma 158.2 was cultured for 8 hr with 200 ,Ci (1 Ci = 37 GBq) of [35S]methionine (New England Nuclear) in 1 ml of methionine-free DME medium supplemented with 5% dialyzed fetal bovine serum. Culture supernatant was then examined by one-dimensional (32) and two-dimensional NaDodSO4/polyacrylamide gel electrophoresis according to the method of Van Blerkom (33) as adapted by Greig et al. (34) . Karyotypic analysis was performed by Hazelton Laboratories America (Vienna, VA). Staphylococcus aureus (Cowan 1) protein A (IgGsorb) was obtained from The Enzyme Center (Boston, MA).
Cell Surface Marker Analysis. For initial screening and analysis of monoclonal antibody binding to cells, a trace radioimmune binding assay (IBA) was used (35) . Binding of rat monoclonal antibody to cells was detected by 1251-labeled GAR (125_-GAR). IBA was carried out on adherent cells (2 x 105 per well) in 96-well plastic tissue culture dishes (Falcon no. 3042 Microtest II) or for cells in suspension in polypropylene tubes. Cells in DME medium supplemented with 1% bovine serum albumin/10 mM NaN3 (DME medium/albumin) were first incubated with saturating amounts of monoclonal antibody for 60 min at 40C, washed three times with DME medium/albumin, and then incubated for an additional 60 min at 40C with I251-GAR. The cells were washed three times with DME medium/albumin and the radioactivity bound was counted in a gamma counter. For flow cytometry, cells in suspension were prepared as above and labeled with fluorescein isothiocyanate-GAR and analyzed on an EPICS V cell sorter (Coulter) by using appropriate scatter windows to gate out cellular debris and cell aggregates and propidium iodide uptake to gate out'dead cells (36 (Fig. 1 ). PEC elicited with thioglycollate, proteose peptone, concanavalin A, C. parvum, and LPS all expressed MA158.2-reactive antigen, though the absolute level of expression was dependent on the nature of the elicitation agent. PEC elicited by thioglycollate, proteose peptone, concanavalin A, and LPS exposed to MAF for 24 hr resulted in an enhanced expression of the 158.2 antigen. In contrast, PEC elicited with C. parvum failed to display enhanced antigen expression following similar treatment. To determine if the enhanced antigen expression observed in MAF-treated PEC was attributable to a highly reactive MO subpopulation rather than a uniform increase in antigen expression, flow cytometry was employed. There was a significant increase (=4-fold) in the mean cell fluorescence of TPM4 treated with MAF as compared to the TPM4 treated with a control lymphokine prepa- (40) . Consistent with this observation is the finding that peak expression of MA158.2-reactive antigen also occurs at 24 hr. of MAF for the times indicated, washed three times with CDME medium, fixed in 1% paraformaldehyde for 15 min at 22°C, and assayed by IBA as described in the legend for Table 2 . Replicate cultures were treated in the same manner, except after washing cells were refed with CDME medium (100 ,ul per well) and maintained in culture for a total time of 24 hr. After a total culture time of 24 (44) (45) (46) , and, more importantly, functional characterProc. NatL Acad Sci. USA 81 (1984) istics (3) (4) (5) (47) (48) (49) (50) It has been reported that lymphokine preparations containing MAF do not render MO fully cytolytic (51) and that MAF instead "primes" MO to become more responsive to a second signal(s) such as LPS, which triggers final expression of tumoricidal properties. The "priming" activity in preparations of MAF has also been reported to be mimicked by cloned murine interferon-y (52 We thank Marcy Hughes and Jo Ann Cavallaro for typing this manuscript. Flow cell cytometry expertise was provided by Dr. Paul Horan and Tom Schmitt and their support is greatly appreciated. We are also grateful to Drs. Nabil Hanna and Deborah Trainer for suggestions and critical reviews of the manuscript.
